Becatecarin (CAS 119673-08-4)
QUICK LINKS
Becatecarin is a semisynthetic water-soluble derivative of rebeccamycin. Becatecarin may act to be used as an antitumor antibiotic, a Topo II (topoisomerase II) inhibitor and a DNA intercalating agent.Becatecarin, a water-soluble diethylaminoethyl analog of rebeccamycin, possesses remarkable antineoplastic properties. It exerts its action by intercalating into DNA, leading to the stabilization of the DNA-topoisomerase complex. This distinctive mechanism results in the potent catalytic inhibition of both topoisomerases I and II, instigating DNA cleavage and triggering apoptosis. Becatecarin is a synthetic diethylaminoethyl analogue of rebeccamycin, a semisynthetic water-soluble derivative with potent antitumor properties. By intercalating into DNA, it stabilizes the DNA-topoisomerase I complex, interfering with the topoisomerase I-catalyzed DNA breakage-reunion reaction and initiating DNA cleavage and apoptosis.
Becatecarin (CAS 119673-08-4) References
- Discovery of antitumor indolocarbazoles: rebeccamycin, NSC 655649, and fluoroindolocarbazoles. | Long, BH., et al. 2002. Curr Med Chem Anticancer Agents. 2: 255-66. PMID: 12678746
- Becatecarin (Helsinn Healthcare). | Rewcastle, GW. 2005. IDrugs. 8: 838-47. PMID: 16254805
- Phase I and pharmacokinetic study of sequences of the rebeccamycin analogue NSC 655649 and cisplatin in patients with advanced solid tumors. | Ricart, AD., et al. 2005. Clin Cancer Res. 11: 8728-36. PMID: 16361560
- Becatecarin (rebeccamycin analog, NSC 655649) is a transport substrate and induces expression of the ATP-binding cassette transporter, ABCG2, in lung carcinoma cells. | Robey, RW., et al. 2009. Cancer Chemother Pharmacol. 64: 575-83. PMID: 19132374
- Phase-II trial of rebeccamycin analog, a dual topoisomerase-I and -II inhibitor, in relapsed 'sensitive' small cell lung cancer. | Schwandt, A., et al. 2012. J Thorac Oncol. 7: 751-4. PMID: 22425925
- Water soluble derivatives of rebeccamycin. | Kaneko, T., et al. 1990. J Antibiot (Tokyo). 43: 125-7. PMID: 2307626
- Morphological and physiological characterization of filamentous Lentzea aerocolonigenes: Comparison of biopellets by microscopy and flow cytometry. | Schrinner, K., et al. 2020. PLoS One. 15: e0234125. PMID: 32492063
- Physics-driven identification of clinically approved and investigation drugs against human neutrophil serine protease 4 (NSP4): A virtual drug repurposing study. | Ahmad, J., et al. 2020. J Mol Graph Model. 101: 107744. PMID: 33032202
- The third-generation EGFR inhibitor almonertinib (HS-10296) resensitizes ABCB1-overexpressing multidrug-resistant cancer cells to chemotherapeutic drugs. | Wu, CP., et al. 2021. Biochem Pharmacol. 188: 114516. PMID: 33713643
- Comparative transcriptome analysis reveals key epigenetic targets in SARS-CoV-2 infection. | Salgado-Albarrán, M., et al. 2021. NPJ Syst Biol Appl. 7: 21. PMID: 34031419
- CROssBAR: comprehensive resource of biomedical relations with knowledge graph representations. | Doğan, T., et al. 2021. Nucleic Acids Res. 49: e96. PMID: 34181736
- Transcriptomics and Proteomics Characterizing the Anticancer Mechanisms of Natural Rebeccamycin Analog Loonamycin in Breast Cancer Cells. | Sun, X., et al. 2022. Molecules. 27: PMID: 36296549
- Hydroxygenkwanin Improves the Efficacy of Cytotoxic Drugs in ABCG2-Overexpressing Multidrug-Resistant Cancer Cells. | Li, YQ., et al. 2022. Int J Mol Sci. 23: PMID: 36361555
- Multitrait genome-wide analyses identify new susceptibility loci and candidate drugs to primary sclerosing cholangitis. | Han, Y., et al. 2023. Nat Commun. 14: 1069. PMID: 36828809
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
Becatecarin, 250 µg | sc-202493 | 250 µg | $354.00 | |||
Becatecarin, 1 mg | sc-202493A | 1 mg | $1022.00 |